
Marianne P. Allen
Examiner (ID: 17617, Phone: (571)272-0712 , Office: P/1647 )
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1818, 1812, 1645, 1805, 1631, 1647 |
| Total Applications | 2168 |
| Issued Applications | 1046 |
| Pending Applications | 251 |
| Abandoned Applications | 885 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17556088
[patent_doc_number] => 11312764
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Immunoglobulin variable domains
[patent_app_type] => utility
[patent_app_number] => 16/695420
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 112
[patent_figures_cnt] => 43
[patent_no_of_words] => 74124
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16695420
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/695420 | Immunoglobulin variable domains | Nov 25, 2019 | Issued |
Array
(
[id] => 15454453
[patent_doc_number] => 20200040051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => FIBROBLAST GROWTH FACTOR (FGF) 1 WITH MUTATION IN THE HEPARIN BINDING DOMAIN AND METHODS OF USE TO REDUCE BLOOD GLUCOSE
[patent_app_type] => utility
[patent_app_number] => 16/662553
[patent_app_country] => US
[patent_app_date] => 2019-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16662553
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/662553 | FIBROBLAST GROWTH FACTOR (FGF) 1 WITH MUTATION IN THE HEPARIN BINDING DOMAIN AND METHODS OF USE TO REDUCE BLOOD GLUCOSE | Oct 23, 2019 | Abandoned |
Array
(
[id] => 15556887
[patent_doc_number] => 20200062855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING
[patent_app_type] => utility
[patent_app_number] => 16/660473
[patent_app_country] => US
[patent_app_date] => 2019-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16695
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/660473 | COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING | Oct 21, 2019 | Abandoned |
Array
(
[id] => 15797231
[patent_doc_number] => 20200121758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRING
[patent_app_type] => utility
[patent_app_number] => 16/657913
[patent_app_country] => US
[patent_app_date] => 2019-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657913
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/657913 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRING | Oct 17, 2019 | Abandoned |
Array
(
[id] => 16175536
[patent_doc_number] => 20200222504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => Platelet-Derived Growth Factor Compositions and Methods for the Treatment of Tendinopathies
[patent_app_type] => utility
[patent_app_number] => 16/653733
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653733
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/653733 | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies | Oct 14, 2019 | Issued |
Array
(
[id] => 15765905
[patent_doc_number] => 20200113970
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH
[patent_app_type] => utility
[patent_app_number] => 16/599397
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7081
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599397
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/599397 | Compositions and methods for promoting hair growth | Oct 10, 2019 | Issued |
Array
(
[id] => 15768851
[patent_doc_number] => 20200115443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => BI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/600075
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6563
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600075
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/600075 | BI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF | Oct 10, 2019 | Abandoned |
Array
(
[id] => 17307372
[patent_doc_number] => 11208465
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Diagnosis of blistering autoimmune disease
[patent_app_type] => utility
[patent_app_number] => 16/591333
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14866
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591333
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/591333 | Diagnosis of blistering autoimmune disease | Oct 1, 2019 | Issued |
Array
(
[id] => 16253516
[patent_doc_number] => 20200262890
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => ENGINEERED POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/573726
[patent_app_country] => US
[patent_app_date] => 2019-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57991
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573726
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/573726 | Engineered polypeptides | Sep 16, 2019 | Issued |
Array
(
[id] => 15994025
[patent_doc_number] => 20200172883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/570157
[patent_app_country] => US
[patent_app_date] => 2019-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570157
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/570157 | Compositions for increasing polypeptide stability and activity, and related methods | Sep 12, 2019 | Issued |
Array
(
[id] => 15553651
[patent_doc_number] => 20200061237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => Gilz Formulations for Wound Healing
[patent_app_type] => utility
[patent_app_number] => 16/541252
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541252
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/541252 | GILZ formulations for wound healing | Aug 14, 2019 | Issued |
Array
(
[id] => 15175409
[patent_doc_number] => 20190358296
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => METHODS FOR TREATING METABOLIC DISORDERS USING FGF
[patent_app_type] => utility
[patent_app_number] => 16/538327
[patent_app_country] => US
[patent_app_date] => 2019-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538327
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/538327 | METHODS FOR TREATING METABOLIC DISORDERS USING FGF | Aug 11, 2019 | Abandoned |
Array
(
[id] => 17314515
[patent_doc_number] => 20210403563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => ANTI-VEGF-PD1 BISPECIFIC ANTIBODY WITH NOVEL STRUCTURE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/980853
[patent_app_country] => US
[patent_app_date] => 2019-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6785
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980853
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/980853 | Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof | Aug 8, 2019 | Issued |
Array
(
[id] => 15267463
[patent_doc_number] => 20190382465
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => Fusion Polypeptides Capable Of Activating Receptors
[patent_app_type] => utility
[patent_app_number] => 16/533585
[patent_app_country] => US
[patent_app_date] => 2019-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533585
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/533585 | Fusion Polypeptides Capable Of Activating Receptors | Aug 5, 2019 | Abandoned |
Array
(
[id] => 15147827
[patent_doc_number] => 20190352391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => Arthritis Treatment
[patent_app_type] => utility
[patent_app_number] => 16/530667
[patent_app_country] => US
[patent_app_date] => 2019-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530667
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/530667 | Arthritis treatment | Aug 1, 2019 | Issued |
Array
(
[id] => 17126236
[patent_doc_number] => 20210301004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/263691
[patent_app_country] => US
[patent_app_date] => 2019-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/263691 | A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE | Jul 31, 2019 | Pending |
Array
(
[id] => 17473972
[patent_doc_number] => 20220081476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => METHOD FOR PREPARING GLY-TB4
[patent_app_type] => utility
[patent_app_number] => 17/266160
[patent_app_country] => US
[patent_app_date] => 2019-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32396
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266160 | METHOD FOR PREPARING GLY-TB4 | Jul 24, 2019 | Abandoned |
Array
(
[id] => 15209775
[patent_doc_number] => 20190367574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => METHOD OF TREATING NASH USING A LONG-ACTING MUTANT HUMAN FIBROBLAST GROWTH FACTOR
[patent_app_type] => utility
[patent_app_number] => 16/520053
[patent_app_country] => US
[patent_app_date] => 2019-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2503
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16520053
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/520053 | Method of treating nash using a long-acting mutant human fibroblast growth factor | Jul 22, 2019 | Issued |
Array
(
[id] => 16238251
[patent_doc_number] => 20200255485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/519920
[patent_app_country] => US
[patent_app_date] => 2019-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519920
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/519920 | PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME | Jul 22, 2019 | Abandoned |
Array
(
[id] => 15083539
[patent_doc_number] => 20190336580
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/520179
[patent_app_country] => US
[patent_app_date] => 2019-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16520179
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/520179 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | Jul 22, 2019 | Issued |